- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01951560
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)
A Phase 1, Single Ascending Dose, Double Blind, Placebo Controlled Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1) or Trauma Patients(Part 2)
The purpose of the first part of this study is to determine the safety and tolerability of ascending doses of valproic acid (also known as Depacon) administered as intravenous infusion (IV) in doses ranging from 15 mg/kg to 250 mg/kg in healthy subjects.
The second part of the study will also be to determine the safety and tolerability of single ascending doses of valproic acid administered as IV in trauma subjects with hemorrhagic shock.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Part 1 of the study will be a single center study intended to assess the safety and tolerability of valproic acid dosages at 15 mg/kg, 30 mg/kg, 60 mg/kg, 90 mg/kg, 120 mg/kg, 150 mg/kg 180 mg/kg, 210 mg/kg and 250 mg/kg. Up to 72 healthy subjects (9 dose groups of 8 subjects) will receive single doses of valproic acid or placebo via a 60-min IV infusion in a ratio of 3:1 active drug: placebo.
Part 2 of the study will be a multicenter, double blind, placebo-controlled study in trauma patients with hemorrhagic shock who are able to give consent or severe trauma patients with hemorrhagic shock in whom a legally authorized representative can give consent. Up to 12 patients (2 dose groups of 6 patients) will receive single doses of valproic acid or placebo via a 60-min IV infusion in a ratio of 2:1 active drug : placebo. The dose levels in Part 2 will be the two highest doses that are demonstrated to have acceptable safety profile based on the review of safety data from Part 1.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- The University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female volunteers between the ages of 18 and 65 years, inclusive, in good health based on medical history, physical examination, ECG, and routine laboratory tests (blood chemistry, hematology, urinalysis, and drug screen).
- Female subjects must be surgically sterilized or postmenopausal. Criteria for menopause are surgical menopause (hysterectomy, oophorectomy) or age > 45 years with absence of menses for greater than 12 months or a serum follicle stimulating hormone (FSH) elevation > 25m IU/mL.(mIU/mL is the unit used to measure human chorionic gonadotropin (hCG) in pregnancy test). Tubal ligation with menses within the past 12 months is not considered to be surgical sterilization.
- Negative urine pregnancy test in female volunteers
- Body mass index (BMI) between 18 kg/m2 and 30 kg/m2
- Subjects must be non-smokers
- Negative alcohol screen
- Willing and able to be confined to the clinical research facility as required by the protocol.
- Willing and able to comply with the investigational nature of the study and able to communicate well with investigators.
- Ability to comprehend and willingness to provide written informed consent in accordance with institutional and regulatory guidelines.
Exclusion Criteria:
- Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies; however, subjects with untreated, asymptomatic, seasonal allergies may be enrolled).
- Subjects with a-amylase >130 U/L or lipase >300 U/L or creatinine > upper limit of normal (ULN)
- Subjects with >2times ULN aspartate aminotransferase (AST) or alanine amino transferase (ALT) or >1.5 times total bilirubin
- Subjects whose screening ECG demonstrates at least one of the following: heart rate > 100 bpm for more than 30 minutes, (the combination of three of the graphical deflections seen on a typical ECG is called the(QRS)) > 120 msec, corrected QT interval (QTc) > 440 msec if male or 450 msec if female, prevalence rate (PR) > 220 msec or any rhythm other than sinus rhythm, sinus bradycardia (HR <40 bpm), or sinus arrhythmia.
- Subjects with a history of alcohol consumption exceeding 14 drinks/week on average within the 6 months before study entry.
- Subjects whose sitting blood pressure is above 140/90 mmHg on 2 evaluations at least 10 minutes apart at screening.
- Subjects who have donated blood in excess of 500 mL within 60 days prior to the first dose of study medication.
- Subjects with a positive result on drug screen, hepatitis B surface antigen (HBsAg), hepatitis C (HCV), or human immunodeficiency (HIV) tests
- Subjects who have used prescription or non-prescription drugs, vitamins, herbal supplements or dietary supplements within 14 days prior to the first dose of study medication. Subjects who have used acetaminophen at doses of < 2 grams/day will be eligible for study entry.
- Subjects who have been treated with an investigational drug within 30 days.
- Subjects who have previously received or are currently taking valproic acid.
- Subjects who have a history of drug abuse.
- Subjects who are not willing to abstain from consuming products containing caffeine (including chocolate), methyl xanthine, or alcohol from Day -1 through the end of the pharmacokinetics (PK) study (day 4 for part 1 subjects).
- Subjects who have had a febrile illness within 5 days prior to the first dose of study medication.
- Subjects with inadequate venous access.
- Subjects vaccinated within 30 days prior to the first dose of study medication. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: valproic acid (Depacon)
Valproic acid by IV infusion over one hour
|
By infusion over 1 hour
Other Names:
|
PLACEBO_COMPARATOR: Isotonic saline solution
The placebo administered by IV infusion over 1 hour
|
By infusion over 1 hour
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicity (DLT)
Time Frame: Subjects will be monitored for 4 days after the one hour infusion. Dose escalation may occur if less than 2 subjects in any cohort of 8 experience DLT.
|
Dose limiting toxicity (DLT) will be defined as drug-related grade 2 (moderate) or higher toxicity (excluding fever, chills, nausea or other possible infusion-related effects).
The maximum tolerated dose (MTD) will be declared at the dose below which 2 or more subjects experience DLT.
|
Subjects will be monitored for 4 days after the one hour infusion. Dose escalation may occur if less than 2 subjects in any cohort of 8 experience DLT.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Hemorrhage
- Shock
- Shock, Hemorrhagic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
Other Study ID Numbers
- VPA-C-002 (Department of Defense/ONR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shock,Hemorrhagic
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Boston Medical Center; Tufts Medical Center and other collaboratorsRecruiting
-
Jason SperryNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHemorrhagic ShockUnited States
-
University of Texas Southwestern Medical CenterUniversity of Washington; Resuscitation Outcomes ConsortiumCompletedHemorrhagic ShockUnited States
-
Assiut UniversityUnknown
-
Assistance Publique - Hôpitaux de ParisTraumabase Group; Capgemini Invent; Ecole polytechnique; EHESS (Ecole des hautes... and other collaboratorsRecruitingWounds and Injuries | Hemorrhagic Shock | Traumatic ShockFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingSepsis | Shock | Hemorrhagic ShockFrance
-
Haukeland University HospitalMinistry of Defence, NorwayCompletedHemorrhagic Shock | Hypovolemic ShockNorway
-
Isfahan University of Medical SciencesCompletedHemorrhagic Shock | IVC Collapsibility IndexIran, Islamic Republic of
-
Cristina MartinezCompleted
-
Haukeland University HospitalVestre Viken Hospital Trust; Oslo University Hospital; University Hospital of... and other collaboratorsCompletedUse of Blood and Plasma in Norwegian Physician-staffed Helicopter Emergency Medical System (ProHEMS)Hemorrhagic ShockNorway
Clinical Trials on Valproic Acid
-
New Mexico Cancer Care AllianceCompleted
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedBipolar DisorderUnited States
-
New Mexico Cancer Care AllianceWithdrawnChronic Myelogenous LeukemiaUnited States
-
University of Sao PauloCompletedParaparesis Spastic TropicalBrazil
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Brain and Central Nervous System TumorsCanada, United States
-
Northwell HealthTerminatedHealthy | Obesity | PharmacokineticsUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCCompleted
-
Nantes University HospitalCompletedProgressive Supranuclear PalsyFrance
-
Johns Hopkins UniversityNational University Hospital of SingaporeWithdrawnNasopharyngeal CarcinomaSingapore